Gujarat Kidney and Super Speciality Ltd

Gujarat Kidney and Superspeciality Limited informed the BSE Limited and National Stock Exchange of India Limited that its management will be attending GIA Healthcare Day with investors and analysts on August 31, 2026, at the Jio World Convention Centre in BKC, Mumbai, from 10:00 AM to 11:00 AM, with the meeting organized by Go India Advisors, the company’s newly engaged Investor Relations and PR agency.

Gujarat Kidney and Super Speciality Limited announced the appointment of Mrs. (Dr) Disha Bharpoda (DIN: 11897794) as an Additional Non-Executive Independent Director, effective August 24, 2026, following a board meeting held on the same date. The appointment is for a term of five years and is subject to approval by the company's members at the next Annual General Meeting. Additionally, the board acknowledged shareholder approval via postal ballot for a special resolution concerning a variation in the objects and terms of utilization of the Initial Public Offering proceeds.

Gujarat Kidney and Super Speciality Limited announced the appointment of Mrs. (Dr) Disha Bharpoda (DIN: 11897794) as an Additional Non-Executive Independent Director, effective August 24, 2026, following a board meeting held on the same date. The appointment, which is subject to shareholder approval at the next Annual General Meeting, is for a term of five years and was recommended by the company’s Nomination and Remuneration Committee. Additionally, the board acknowledged shareholder approval via postal ballot for a special resolution concerning a variation in the objects and terms of utilization of the Initial Public Offering proceeds.

Gujarat Kidney & Super Speciality Ltd share price inched up 0.48% to Rs 136.65 after the company's net profit expanded by 10.14% to Rs 5.32 crore, while revenue from operations increased 12.13% to Rs 34.29 crore in Q2FY26 over Q1FY26. The market capitalization of Hospital industry group stocks on BSE stood at Rs 5.19 lakh crore, rising 7.50%. It has slipped by 1.93% over last one week and spiked sharply by 28.90% in last one month while the market capitalization of Gujarat Kidney & Super Speciality Ltd has marginally improved by 1.67% and 0.44% in the same period respectively. Profit before tax (PBT) of Gujarat Kidney & Super Speciality Ltd stood at Rs 6.96 crore in Q2 FY26, declining 7.08% year-on-year, and expanding by 48.40% quarter-on-quarter. EBITDA came in at Rs 8 crore, dropping 10.69% YoY and surging by 37.57% sequentially. Total expenses grew marginally by 6.05% to Rs 27.35 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 4.34 crore, witnessing a sharp rise of 28.78% YoY, while employee benefits expense was at Rs 5.29 crore, registering a marginal contraction of 1.12% YoY. For the TTM ended FY26, revenue from operations soared by 743.61% to Rs 40.24 crore, while net profit surged by 455.56% to Rs 9.5 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 322% to Rs 16.4 crore, and PBT surged 462.56% to Rs 12.77 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 13.61 crore in FY26, as against Rs 1.21 crore in FY25. Gujarat Kidney & Super Speciality Ltd jumped 29.96% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 3.05% during the same period.

Gujarat Kidney And Superspeciality Limited will hold a board meeting on Friday, August 14, 2026, to consider the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, according to a filing with the BSE Limited and National Stock Exchange of India Limited. The trading window for the company will be closed from June 1, 2026, until 48 hours after the announcement of the audited financial results for the quarter ended June 30, 2026.

Net profit of Gujarat Kidney & Super Speciality rose 293.75% to Rs 5.04 crore in the quarter ended March 2026 as against Rs 1.28 crore during the previous quarter ended March 2025. Sales rose 212.68% to Rs 30.58 crore in the quarter ended March 2026 as against Rs 9.78 crore during the previous quarter ended March 2025. For the full year,net profit rose 64.72% to Rs 15.50 crore in the year ended March 2026 as against Rs 9.41 crore during the previous year ended March 2025. Sales rose 103.80% to Rs 82.01 crore in the year ended March 2026 as against Rs 40.24 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales30.589.78 213 82.0140.24 104 OPM %20.6026.79 -32.8541.13 - PBDT6.192.50 148 25.9316.06 61 PBT4.691.60 193 21.2312.77 66 NP5.041.28 294 15.509.41 65 Powered by Capital Market - Live

Gujarat Kidney & Super Speciality will hold a meeting of the Board of Directors of the Company on 28 May 2026.

Net profit of Gujarat Kidney & Super Speciality rose 17.60% to Rs 2.94 crore in the quarter ended December 2025 as against Rs 2.50 crore during the previous quarter ended December 2024. Sales rose 97.20% to Rs 23.25 crore in the quarter ended December 2025 as against Rs 11.79 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales23.2511.79 97 OPM %29.6839.02 - PBDT6.364.48 42 PBT5.033.60 40 NP2.942.50 18 Powered by Capital Market - Live

Gujarat Kidney & Super Speciality has postponed the meeting of the Board of Directors which was scheduled to be held on 13 February 2026. The meeting will now be held on 14 February 2026.Powered by Capital Market - Live

Gujarat Kidney & Super Speciality will hold a meeting of the Board of Directors of the Company on 13 February 2026.Powered by Capital Market - Live